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Introduction: Lysinuric protein intolerance (LPI), a rare autosomal recessive transport 
disorder of cationic amino acids lysine, arginine and ornithine, affects intestines, 
lungs, liver and kidneys. LPI patients may display potentially life- threatening bleeding 
events, which are poorly understood.
Aims: To characterize alterations in haemostatic and fibrinolytic variables associated 
with LPI.
Methods: We enrolled 15 adult patients (8 female) and assessed the clinical ISTH/
SSC- BAT bleeding score (BS). A variety of metabolic and coagulation assays, includ-
ing fibrin generation test derivatives, clotting time (CT) and clot lysis time (CLT), 
thromboelastometry (ROTEM), and PFA-100 and Calibrated Automated Thrombogram 
(CAT), were used.
Results: All patients had mild- to- moderate renal insufficiency, and moderate bleed-
ing tendency (BS 4) without spontaneous bleeds. Mild anaemia and thrombocytope-
nia occurred. Traditional clotting times were normal, but in contrast, CT in fibrin 
generation test, and especially ROTEM FIBTEM was abnormal. The patients showed 
impaired primary haemostasis in PFA, irrespective of normal von Willebrand factor 
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1  | INTRODUC TION
Lysinuric protein intolerance (LPI) is a rare autosomal reces-
sive transport disorder of the cationic amino acids lysine, argi-
nine and ornithine, affecting intestine, lungs, liver and renal 
tubules.1-4 Because of impaired intestinal absorption and tubular 
re- absorption in the kidney, plasma concentrations of lysine, ar-
ginine and ornithine are low in patients with LPI. A deficiency of 
arginine and ornithine restricts the function of the urea cycle and 
leads to hyperammonemia after dietary loads of protein. Lysine 
deficiency may influence the immune system and growth and 
may cause haematological abnormalities. Signs and symptoms 
of LPI include strong protein aversion in late infancy, failure to 
thrive, short stature, muscular weakness, osteoporosis and hep-
atosplenomegaly. Hypercholesterolemia, hypertriglyceridaemia 
and deficient B- cell function have also been reported.5-7 Renal 
insufficiency is a common complication associated with LPI that 
may progress to end- stage renal disease requiring renal trans-
plantation. Severe pulmonary complications, including pulmonary 
fibrosis and alveolar proteinosis, may also occur.8-11 Several LPI 
patients with hemophagocytic lymphohistiocytosis syndrome 
(HLH) have been reported in the literature. Serum ferritin is con-
stantly markedly elevated in LPI patients, further referring to on-
going hemophagocytosis.12
Lysinuric protein intolerance is more prevalent in Finland (1 in 
60 000) than elsewhere in the world due to Finnish disease heritage, 
but several patients have been reported from, for example, Italy, 
Tunisia, and Japan.13,14 LPI is caused by bi- allelic mutations in the 
gene SLC7A7, which encodes the y+LAT1 protein, the catalytic light 
chain subunit of the heteromeric amino acid transporter.15-18 All the 
Finnish patients share the same mutation, a substitution of T for A at 
cDNA position 1181- 2A →T (LPIFin).
2
It has been recognized that LPI patients may display bleeding 
events. Even fatal haemorrhage has been observed postpartum and 
otherwise, but the mechanisms rendering the LPI patients prone to 
bleeding are unknown, although low platelet counts, low fibrinogen, 
high D- dimer and elevated levels of thrombin- antithrombin complex 
(TAT) have been observed.19,20 The prevalence and pathogenesis of 
coagulopathy associated with LPI has not been systemically evalu-
ated, and case reports on this subject are sparse. The aim of this 
study was to characterize alterations in haemostatic and fibrinolytic 
markers in LPI patients compared with controls and the renal impair-
ment. The motivation for this study is the unmet need to guide the 
perioperative management of these patients in general, specifically 
during renal transplantation.
2  | METHODS
2.1 | Subjects
The diagnostics and annual follow- up of Finnish LPI patients is cen-
tralized to the Department of Pediatrics at the Turku University 
Hospital. The current study cohort consisted of 15 adult LPI patients 
(8 women) available for analysis. The median age of the participants 
was 45 years (ranging 23- 60 years). Our study was approved by the 
ethics committee of Turku University Hospital, and informed con-
sent was obtained in accordance with the Declaration of Helsinki. 
Eleven of the patients used lysine supplementation. One patient had 
regular dipyridamole/acetylsalicylic acid medication due to a history 
of a transient ischaemic attack. One patient had previously under-
gone a splenectomy, and another had both a kidney transplant and 
splenectomy. At the time of the study, one patient had developed 
end- stage renal disease and needed regular erythropoietin injec-
tions to treat renal anaemia. Control plasma was collected from non-
matched volunteer donors in the same age range as our LPI patients. 
All volunteers had normal body mass index, no known illnesses, 
medications nor any history of bleeds.
2.2 | Sample collection
Blood samples were collected in citrate anticoagulant (109 mmol/L so-
dium citrate) from the patients and healthy volunteers. Platelet- poor 
activity, but together with lowered fibrinogen and FXIII. Thrombin generation (TG) 
was reduced in vitro, according to CAT- derived endogenous thrombin potential, but 
in vivo TG was enhanced in the form of circulating prothrombin fragment 1 and 2 
values. Very high D- dimer and plasmin- α2- antiplasmin (PAP) complex levels coincided 
with shortened CLT in vitro.
Conclusions: Defective primary haemostasis, coagulopathy, fibrin abnormality 
(FIBTEM, CT and CLT), low TG in vitro and clearly augmented fibrinolysis (PAP and 
D- dimer) in vivo were all detected in LPI. Altered fibrin generation and hyper-
fibrinolysis were associated with the metabolic and renal defect, suggesting a patho-
genetic link in LPI.
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plasma (PPP) was processed by centrifugation at 2500 g for 15 minutes 
at room temperature. PPP was stored in aliquots at −80°C.
2.3 | LPI routine follow- up
All LPI patients were clinically examined (weight, blood pressure), 
including routine follow- up metabolic assays: total blood cell count, 
plasma ferritin, plasma alanine aminotransferase (ALT), plasma 
creatinine (P- Crea), urinary creatinine (U- Crea), serum cystatin C, 
urine beta2- microglobulin for an early marker of renal insufficiency, 
plasma and urinary amino acids, including plasma lysine (P- LYS) and 
urinary lysine (U- LYS), plasma ammonia (P- NH4), total plasma choles-
terol, low- density lipoprotein (LDL), high- density lipoprotein (HDL), 
triglycerides, plasma prealbumin, and capillary blood gas analysis. To 
estimate the glomerular filtration rate (eGFR), the Chronic Kidney 
Disease Epidemiology Collaboration (CKD- EPI) equation was used.21 
Urinary lysine levels without creatinine correction were calculated 
by multiplying U- LYS with U- Crea.
2.4 | Clinical evaluation of bleeding tendency
The ISTH/SSC- BAT questionnaire 22 for scoring the severity of the 
bleeding tendency was used to evaluate the clinical impact of LPI on 
haemostasis. Normal values of this bleeding score (BS) for men are 
<4 points and <6 points for women.23
2.5 | Coagulation biomarkers and primary 
hemostasis PFA- 100
The following routine coagulation assays were used: blood cell 
count, prothrombin time (PT, Nycotest PT, Axis- Shield PoC As, Oslo, 
Norway), activated partial thromboplastin time (APTT, Actin FSL, 
Siemens Healthcare Diagnostics, Erlangen, Germany), thrombin time 
(TT) (BC Thrombin reagent, Siemens Healthcare Diagnostics) and 
von Willebrand factor activity (VWF:Ac) assay (INNOVANCE VWF 
Ac., Siemens Healthcare Diagnostics). Primary hemostasis was stud-
ied with either epinephrine (EPI) or adenosine- 5- diphosphate (ADP) 
and recorded as closure times of collagen membrane cartridges in 
the PFA- 100 (Siemens Healthcare Diagnostics).
Also, FXIII:C activity (Berichrom chromogenic FXIII, Siemens 
Healthcare Diagnostics), fibrinogen (modified Clauss method, 
Multifibren U, Siemens Healthcare Diagnostics), D- dimer (immuno-
turbidometric Tina- quant D- Dimer, Roche Diagnostics, Mannheim, 
Germany), plasminogen and α2- antiplasmin (Diagnostica Stago 
S.A.S. Asnières sur Seine, France), F1 + 2 (Enzygnost monoclonal, 
Siemens Healthcare Diagnostics), plasmin α2- antiplasmin complex 
(PAP) micro Elisa (DRG Diagnostica, Marburg, Germany) and TAFI 
activity (PEFA kit, Pentapharm, Basel, Switzerland) were assessed.
2.6 | ROTEM
Thromboelastometric variables were studied with a ROTEM device 
(TEM International GmbH, Munich, Germany) at 37°C in citrated 
whole blood according to the manufacturer’s instructions. ROTEM 
tracings were recorded up to 60 minutes. EXTEM uses TF as an ac-
tivator and explores extrinsic pathway, and INTEM is activated by 
phospholipids and ellagic acid, mimicking intrinsic pathway. Both 
EXTEM and INTEM are influenced by platelets and fibrinogen. 
FIBTEM is a modification of EXTEM, showing the isolated effect of 
fibrinogen under cytochalasin D- induced platelet inhibition. Clotting 
time (CT s), clot formation time (CFT s), clot formation after 10 min-
utes (A10 mm), maximum clot firmness (MCF mm) and maximum 
lysis (ML %) were collected. Further details about thromboelastom-
etry are described elsewhere.24
2.7 | Calibrated Automated Thrombogram (CAT)
Thrombin generation (TG) was measured in vitro with CAT 
(Labscan, Thermo Fisher, Helsinki, Finland) assay using the 
Thrombinoscope software (Thrombinoscope, Maastricht, The 
Netherlands) and reagents (Diagnostica Stago, Asnières sur Seine 
Cedex, France), in the absence of corn trypsin inhibitor and ac-
cording to the manufacturer’s instructions.25 A reaction was trig-
gered with 1 pM TF and 4 μmol/L PL (PPP reagent low). The CAT 
variables included lag time (time to initiation of thrombin forma-
tion, minute), endogenous thrombin potential (ETP; the area under 
the curve; nmol/L thrombin × min) and peak (maximum thrombin 
concentration, nmol/L).
2.8 | Fibrin generation and clot lysis test
To assess fibrin generation and clot lysis, optical density (OD) of clot-
ting plasma, triggered with TF, was measured in the presence of tissue 
plasminogen activator (tPA) to induce fibrinolysis. Carboxypeptidase 
inhibitor (Sigma Aldrich St. Louis, MO, USA) was included in paral-
lel incubations to inhibit activated thrombin- activatable fibrinolysis 
inhibitor (TAFIa). Typically, 75 μL plasma was mixed with 75 μL tris- 
buffered saline containing the carboxypeptidase inhibitor when in-
dicated and start reagents (TF, phospholipids, tPA and CaCl2 at final 
concentrations of 0.5 pmol/L, 4 μmol/L, 50 ng/mL, and 15 mmol/L, 
respectively). ODmax was derived directly from the OD tracing 
measured at 405 nm. For clotting time (CT) and clot lysis time (CLT) 
measurements, the first derivative of the OD tracing was used. CT 
is defined as the time from start reagent addition to maximal rate of 
fibrin generation (first peak in the plot time against first derivative 
OD). CLT is defined as the time between the maximal rate of fibrin 
generation and the maximal rate of clot lysis (second peak in the first 
derivative plot).
2.9 | Statistics
The median and the range were calculated and reported for all meas-
urements. The Shapiro- Wilk normality test was performed. Groups 
were compared using the Mann- Whitney test. Correlations were 
calculated with the Spearman correlation coefficient, also using lin-
ear regression models where pertinent. IBM SPSS Statistics 22 was 
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used to calculate statistics, and P- values <.05 were considered sta-
tistically significant.
3  | RESULTS
3.1 | Bleeding score
Nine patients presented with normal BS. Six patients had elevated 
BS (Table 1), and three of them were women. Median BS for women 
was 5 (range 0- 9), and for men 2 (range −1- 6) points. Two of the three 
women had experienced severe postpartum haemorrhage. Besides 
labour, one of these two women also bled during a splenectomy 
due to abdominal trauma and kidney transplant surgery. The third 
woman had menorrhagia combined with mucocutaneous bleeds. 
One man bled after a splenectomy due to spontaneous cyst rup-
ture, the other had gastrointestinal (GI) haemorrhage and the third 
had multiple mucocutaneous bleeds related to dental procedures. In 
general, most common bleeding manifestations occurred from minor 
wounds, oral cavity, after tooth/teeth extraction, after surgery or 
major trauma, menorrhagia and postpartum haemorrhage. Two 
women had normal labour and puerperium, and one man underwent 
minor surgery without bleeding complications. Other seven patients 
were not subjected to surgical procedures. No muscle hematomas, 
haemarthrosis nor other spontaneous bleeds, except for the one GI 
bleed, were reported. Ten patients had both mild anaemia and iron 
substitution (Table 1).
3.2 | Routine clinical chemistry analyses
The plasma levels of ALT were moderately elevated in three patients, 
as was NH4 (up to 62 μmol/L) in four patients, but prealbumin was 
normal in all, excluding major liver impairment in our patients. Eleven 
patients had elevated plasma creatinine concentration, and 12 pa-
tients had reduced eGFR. Urinary creatinine (U- crea) measured from 
12 patients was normal. Serum cystatin C was also elevated in 10 pa-
tients. Only one patient had normal urine beta2- microglobulin, while 
it was elevated in all others. P- LYS was reduced in four patients, and 
U- LYS was high in all 12 with the measurement available. Capillary 
blood gas analysis in 13 patients showed normal pH in 7, whereas 
only three presented with normal base excess, and five patients had 
a normal bicarbonate level (Table 2).
Hyperlipidaemia was common, especially hypertriglyceridae-
mia. Most patients (10/12) had elevated total cholesterol. LDL was 
measured in 12 patients, but only 4 had normal levels. Five pa-
tients had normal but the rest had low HDL. Moreover, 12 patients 
had combined hyperlipidaemia, while only 3 patients had normal 
TABLE  1  ISTH- BAT bleeding score
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Cumulative
Sex W W M W W M W M M W M W M M W
Age 40 48 49 23 34 60 29 52 23 45 46 51 40 43 48
Epistaxis 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1
Cutaneous bleeding 1 1 0 1 0 3 1 0 0 0 1 1 0 1 0 10
Bleeding from minor 
wounds
0 0 0 1 0 0 0 0 0 2 0 1 0 0 0 4
Oral cavity bleeding 1 0 0 1 1 0 0 0 1 1 1 0 1 1 0 8
Bleeding after Tooth/
Teeth extraction
3 0 −1 0 2 0 0 0 −1 3 3 −1 3 0 0 11
Gastrointestinal 
bleeding
0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 2
Bleeding after 
Surgery or Major 
trauma
0 0 0 0 0 0 0 4 0 0 0 2 0 0 0 6
Muscle hematomas 
(spontaneous)
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Haemarthrosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Anaemia + + + + + + + + + + 10
Iron substitution + + + + + + + + + + 10
Family history of 
bleeds
+ + + + + 5
Menorrhagia 0 0 2 2 0 2 2 3 11
Postpartum 
haemorrhage
3 −1 0 3 5
Cumulative 8 0 −1 5 5 3 1 4 0 9 7 8 4 2 3
W, women; M, men.
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triglycerides. Ten patients had cholesterol medication (simvasta-
tin), but only one patient had normal cholesterol values without 
medication. Four patients reached normal LDL levels with their 
medication, whereas six remained hypercholesterolemic (Table 2).
3.3 | Blood cell counts, PFA- 100, coagulation 
activity and D- dimer
Median haemoglobin in women was 123 g/L (range 109- 137 g/L) and 
131 g/L in men (ranging 106- 147 g/L). Six presented with mild throm-
bocytopenia. White blood cell count was normal, whereas plasma 
ferritin levels were high in all patients (Table 3). Although none of the 
patients had the diagnosis of HLH, 11/15 patients met 3 of its 8 diag-
nostic criteria,26 of which 5 would indicate HLH. These observations 
included splenomegaly, hypertriglycerideamia or hypofibrinogen-
emia and ferritin levels exceeding 500 μg/L. PT, APTT, and TT and 
VWF:Ac were all normal (Table 3). However, despite the normal 
VWF:Ac, only four patients had normal PFA closure time in the epi-
nephrine cartridge, being prolonged among the others (Table 3). ADP 
closure time was measured for 11 patients, all showing prolongation, 
coinciding with the prolonged EPI closure times. Platelet count and 
EPI closure time correlated (r = −.55; P = .03), whereas the platelet 
count did not correlate with ADP closure time or VWF:Ac levels 
(Table S1 on the individual platelet counts and PFA-100 results).
Functional fibrinogen level was low, although in the normal 
range, but four patients exhibited fibrinogen below 1.7 g/L without 
prolonged thrombin time (Table 3). Median FXIII:C was also low, and 
only four patients had FXIII:C activity within the reference range 
Variable
Metabolic and renal 
markers Reference range LPI patients
Hepatic markers
ALT Plasma (U/mL) W: <35 28 (15- 34)
M: <50 38 (20- 150)
NH4 ion Plasma (μmol/L) <50 37 (16- 62)
Prealbumin Serum (g/L) 0.2- 0.4 0.3 (0.2- 0.4)
Renal markers
Creatinine Plasma (μmol/L) W: 50- 90 128 (68- 201)
M: 60- 100 186 (76- 362)
Creatinine Urine (mmol/L) W: 1.7- 19.4 5.3 (3.0- 8.5)
M: 2.3- 23.5 8.1 (1.9- 15.8)
Cystatin C Serum (mg/L) 0.6- 1.1 1.4 (0.6- 2.5)
Beta2- 
microglobulin
Urine (mg/L) 0- 0.3 19.2 (0.05- 97)
eGFR (mL/min/
m2)
44 (16- 105)
LYS Plasma (μmol/L) 114- 289 132 (69- 172)
LYS Urine (μmol/
mmolCrea)
2- 63 406 (112- 1076)
Lipids
Total cholesterol Plasma (mmol/L) <5 5.8 (3.8- 8.6)
LDL Plasma (mmol/L) <3 3.5 (2.0- 4.4)
HDL Plasma (mmol/L) W: >1.2 1.2 (1.1- 1.4)
M: >1.0 1.1 (0.5- 1.3)
Triglycerides Plasma (mmol/L) <2.0 2.6 (0.9- 7.1)
Capillary blood gas Blood 7.35- 7.45 7.35 (7.26- 7.42)
pH
pCO2 (kPa) 4.5- 6.0 4.8 (3.1- 7.7)
BE (mmol/L) −2.5- +2.5 −4.2 (−10.5 to −1.3)
Bicarbonate 
(mmol/L)
22- 26 21 (13- 23)
ALT, alanine aminotransferase; NH4, ammonium; eGFR, estimated glomerular filtration rate; LYS, lysine; 
LDL, low- density lipoprotein; HDL, high- density lipoprotein; BE, base excess; W, women; M, men.
Data for LPI patients are given as median (range).
Reference range for eGRF: age 18- 39 years >89, 40- 49 years >83, 50- 59 years >77, 60- 69 years >69.
TABLE  2 Routine metabolic and renal 
follow- up
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(Table 3). However, the most striking and uniform finding was the 
elevated D- dimer level in all patients (Table 3, individual fibrinogen, 
FXIII and D- dimer in Table S1).
3.4 | In vitro and in vivo thrombin generation
In vitro thrombin generation (TG), as determined by the TF- triggered 
CAT, was partially impaired compared with healthy controls. Lag 
time (Figure 1A) and peak TG (Figure 1B) did not differ from healthy 
controls. However, ETP was significantly reduced in LPI (P = .02) 
(Figure 1C). In contrast, circulating biomarker F1 + 2 implied strong in 
vivo TG (Table 3), as it exceeded 1200 (range 961 - >1200) pmol/L. In 
healthy individuals, the F1 + 2 median was 178 (range 91- 272) pmol/L.
3.5 | In vitro fibrin clot formation
In ROTEM, some variables differed from normal in LPI patients. As 
expected, FIBTEM MCF recognized fibrinogen levels below the ref-
erence range (Table 3). In addition, seven patients had decreased 
FIBTEM MCF, beyond the four with fibrinogen level <1.7 g/L 
(Table 3). Besides low fibrinogen, low FXIII:C levels may contrib-
ute to FIBTEM MCF, and indeed, FXIII:C showed correlation with 
FIBTEM MCF (r = .63, P = .01). INTEM CT was normal, but six pa-
tients showed prolonged CFT, and four displayed declined MCF. 
EXTEM CT and CFT were prolonged in seven patients, and MCF was 
reduced in five. All EXTEM variables and INTEM CFT, A10 and MCF 
correlated significantly with fibrinogen levels, but not with platelet 
counts. Both INTEM and EXTEM ML were within reference ranges 
(Table 4). Fibrin clot formation triggered with low TF and was traced 
by ODmax measurement, revealing a median CT that was signifi-
cantly prolonged in LPI compared to controls (P < .001) (Figure 1E). 
The median ODmax was decreased in LPI (P = .03) (Figure 1D).
3.6 | Fibrinolysis
As a sign of enhanced in vivo fibrinolysis, together with D- dimer, cir-
culating PAP levels were also extremely high, exceeding 2000 μg/L 
and the calibration curve range. In healthy individuals, the median 
PAP was 638 μg/L (range 430- 862 μg/L). In comparison with healthy 
controls, median plasminogen was elevated (P = .01) (Figure 2A), 
while α2- antiplasmin levels were lower (P < .001) (Figure 2B). This 
resulted in clearly higher plasminogen/α2- antiplasmin ratio (median 
1.50; range 1.10- 2.02) than in healthy controls (0.96; range 0.82- 
1.16) (P < .001) indicating increased fibrinolytic capacity in LPI. TAFI 
levels were slightly reduced in 5 patients (Table 3). Again, compatible 
with enhanced fibrinolysis in general, LPI patients showed shorter 
CLT (P < .01) (Figure 2C) than healthy controls.
3.7 | Clinical, coagulation and fibrinolysis biomarker 
correlations and renal impairment
Renal function markers eGFR and Cystatin C correlated with uri-
nary lysine levels (r = .63, P = .03 and r = −.64, P = .03, respectively). 
Intriguingly, renal function also correlated with both fibrin forma-
tion and fibrinolytic capacity (Table 5). Accordingly, creatinine, 
eGFR, cystatin C, base excess and bicarbonate levels all correlated 
with impaired fibrin formation (ODmax), decreased α2- antiplasmin 
and elevated D- dimer (Table 5). In addition, creatinine correlated 
negatively with fibrinogen and FIBTEM MCF (r = −.56, P = .03 and 
r = −.57, P = .03, respectively), unlike other renal markers.
4  | DISCUSSION
In clinical management, the bleeding disorder associated with 
LPI should alert to act appropriately, as upon LPI progression, 
TABLE  3 Haematologic and fibrinolytic variables
Variable Reference range LPI patients
Blood cell count
Haemoglobin (g/L) W: 117- 155 123 (109- 137)
M: 134- 67 131 (106- 147)
Erythrocytes 
(1012/L)
W: 3.9- 5.2 4.3 (3.5- 4.6)
M: 4.2- 5.7 5.0 (3.5- 5.4)
Ferritin (μg/L) W: 5- 100 995 (678- 9069)
M: 10- 220 2075 (599- 5000)
White blood cells 
(109/L)
3.4- 8.2 5.3 (3.5- 10.6)
Platelets (109/L) 150- 360 154 (95- 309)
Platelet function
PFA- epinephrine 
(s)
82- 150 179 (102- 300)
PFA- ADP (s) 62- 100 115 (102- 162)
Coagulation markers
VWF:activity (%) 44- 183 110 (47- 211)
PT (%) 70- 130 103 (77- 160)
APTT (s) 23- 33 25 (20- 29)
TT (s) 17- 25 22 (19- 30)
Fibrinogen (g/L) 1.7- 4.0 2.5 (1.0- 4.3)
FXIII (%) 76- 156 58 (27- 141)
Prothrombin 
fragment 1 + 2 
(pmol/L)
53- 217 > 1200 
(961- >1200)
Fibrinolysis
Plasminogen (%) 80- 120 120 (91- 155)
α2- antiplasmin (%) 80- 120 88 (50- 105)
Plasmin- 
antiplasmin 
complex (μg/L)
47- 562 >2000
D- dimer (mg/L) <0.5 32 (12- 109)
TAFI (%) 64- 125 72 (48- 121)
PT, prothrombin time; APTT, activated partial thromboplastin time; TT, 
thrombin time; FXIII, factor XIII; TAFI, thrombin-activatable fibrinolysis 
inhibitor; W, women; M, men.
Data for LPI patients are given as median (range).
e318  |     PITKÄNEN ET al.
many patients develop end- stage renal disease, requiring inva-
sive procedures, for example dialysis and renal transplantation.9 
Mucocutaneous bleeds mainly triggered with invasive and surgical 
interventions or postpartum are typical. We encountered impaired 
primary haemostasis and strongly elevated thrombin formation 
and fibrinolysis activation in vivo, while subsequently the in vitro 
coagulation responses were attenuated. Based on previous studies 
and now confirmed by ours, renal insufficiency in LPI associates with 
lysine loss in urine.27 According to our study, markers of abnormal fi-
brin and enhanced fibrinolysis associated with metabolic abnormali-
ties and renal insufficiency.
Our study carries some limitations. We did not include a matched 
control group with renal insufficiency to the study design. The com-
plex pathogenesis of renal diseases carries several variants with 
highly specific alterations in the coagulation and fibrinolytic sys-
tem, rendering the choice of the potential control group difficult.28 
Impaired primary haemostasis,29,30 hypercoagulability and hypo- as 
well as hyperfibrinolysis have been described to associate with dete-
riorating kidney function.31-34 However, we observed approximately 
20- fold higher levels of D- dimer in LPI as reported for other patients 
with chronic kidney disease (CKD) in general 31,32 while fibrinogen, 
elevated in CKD,34 was low to normal in LPI. One laboratory- related 
limitation is the absence of the second step of centrifugation during 
our sample collection, which is recommended for the CAT assay, but 
the control samples were handled in the same manner.
Kayanoki et al20 have suggested that LPI patients exhibit dis-
seminated intravascular coagulation (DIC) due to reduced nitric 
oxide production. Our results show elevated levels of F1 + 2, D- 
dimer, and PAP may indeed support this suggestion. However, 
F IGURE  1 Thrombin generation and fibrin clot formation. LPI patients were compared with healthy controls. The median lag time (A), in 
Calibrated Automated Thrombogram (CAT) was 4.8 min (range 3.5- 9.5 min) vs control 5.6 min (range 3.8- 6.7 min) (not significant between 
the groups, NS). CAT median peak thrombin generation (B), was 150 nmol/L (range 60- 230 nmol/L), while in control, it was 160 nmol/L (range 
40- 310 nmol/L) (NS). Endogenous thrombin potential (ETP) (C), in CAT was reduced (median 750 nmol/L/min; range 440- 1270 nmol/L/min) vs 
controls (median 1170; range 540- 1690 nmol/L/min) (P = .02). Fibrin clot formation traced by ODmax was reduced (median 0.49; range 0.11- 
0.90) vs controls (median 0.63; range 0.26- 1.08) (P = .03) (D). ODmax derivative clotting time (CT) (E), was prolonged (median 3.41 min; range 
2.79- 5.24 min) vs controls (median 2.64 min; range 2.30- 3.03 min) (P < .001). Lines represent median and range. * P = .03, ** P = .02, *** P < .001
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TABLE  4 ROTEM
Variable ROTEM variables Reference range LPI patients
EXTEM CT (s) 38- 79 72 (61- 213)
CFT (s) 34- 159 141 (88- 425)
MCF (mm) 50- 72 52 (35- 73)
ML (%) 0- 15 1 (0- 14)
INTEM CT (s) 100- 240 178 (149- 214)
CFT (s) 30- 110 109 (59- 702)
MCF (mm) 50- 72 55 (25- 73)
ML (%) 0- 15 0 (0- 14)
FIBTEM MCF (mm) 9- 25 9 (3- 20)
CT, clotting time; CFT, clot formation time; MCF, mean clot firmness; ML, 
maximum lysis.
Data for LPI patients are given as median (range).
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thrombocytopenia was mild, and normal PT, APTT and VWF activ-
ity exclude significant coagulation factor consumption. Fibrinogen 
and FXIII levels varied from low to normal. Altered EXTEM and 
INTEM variables in ROTEM correlated with low fibrinogen levels, 
but not with platelet counts, suggesting that in LPI poor fibrin for-
mation contributes to impaired clot formation, but the mild throm-
bocytopenia does not. Our in vitro coagulation assays revealed 
reduced ETP and prolonged CT. ETP displays thrombin predomi-
nantly generated after clot formation,35 and the clots formed by 
low concentrations of thrombin are less resistant to fibrinoly-
sis.36,37 Elevated plasminogen/α2- antiplasmin ratio even further 
promotes fibrinolysis,38 as evidenced by shortened CLT in fibrin 
generation- clot lysis test. We conclude that impaired primary hae-
mostasis and minor consumption coagulopathy together with en-
hanced fibrinolysis may explain the bleeding tendency associated 
with LPI.
We herein suggest an alternative mechanism for the high F1 + 2, 
PAP, and D- dimer and propose that this may partially reflect im-
paired hepatic clearance. Although y+LAT- 1 is not expressed in liver, 
hepatic enlargement with relevant histopathological changes is 
found in the majority of LPI patients.4 Indicators of in vivo coagula-
tion (F1 + 2) and fibrinolysis (D- dimer and PAP) are breakdown prod-
ucts or protease- inhibitor complexes with relatively short half- lives. 
The hepatic clearance of these molecule complexes may be delayed 
in LPI due to liver involvement, as seen in cirrhosis.39 The above- 
mentioned metabolic complexes are highly elevated in LPI, albeit 
clinical liver disease is not present. In addition, lipid metabolism of 
combined hyperlipidaemia 40 further overloads liver in LPI. Further 
studies are required to ascertain whether impaired hepatic clearance 
contributes to elevated levels of in vivo indicators of coagulation and 
fibrinolysis in LPI.
Our LPI patients presented with moderate renal insufficiency, 
confirmed by elevated creatinine, cystatin C and urine beta2- 
microglobulin levels. At normal pH, base excess and bicarbonate lev-
els accorded with systemic acidosis due to chronic renal insufficiency 
and tubular dysfunction via LPI.41 Pathophysiological mechanisms of 
renal impairment in LPI are not fully elucidated, but several explana-
tions have been suggested. Lysine trapped inside the proximal tubu-
lar cells causes direct toxicity and apoptosis.27,42 Furthermore, oral 
lysine supplementation in rats promotes proteinuria and inhibits al-
bumin reabsorption by the proximal tubular cells.42 According to the 
second hypothesis, arginine accumulation in renal cells may promote 
local synthesis of nitric oxide and trigger inflammation and immune 
system overstimulation, causing immune glomerulopathy.41,43,44 
The severity of renal insufficiency in LPI correlated with the overt 
fibrinolysis, as α2- antiplasmin and D- dimer clearly associated with 
the loss of renal function. During hyperfibrinolysis, altered plasmin-
ogen/α2- antiplasmin ratio may lead to plasminemia, which is harmful 
to kidneys.45 Also, ODmax, a variable derived from fibrin generation 
tracings, and affected in particular by both the fibrinogen level and 
the amount of thrombin generated, revealed a significant association 
with the markers of renal function.
F IGURE  2 Fibrinolysis markers. LPI patients were compared with healthy controls. Median plasminogen (A), in LPI was 120% (range 91%- 
155%) (P = .01) vs 100% (range 92%- 111%) in controls (P = .01). Median α2- antiplasmin (B), in LPI was 88% (range 50- 105) vs 101% in controls 
(range 95%- 113%) (P < .001). Median fibrin clot lysis time (CLT) (C), in LPI was 30 min (24- 49 min) and 42 min in controls (range 31- 91 min) 
(P < .01). Lines represent median and range. * P = .01, ** P < .01
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Creatinine eGFR Cystatin C BE Bicarbonate
ODmax r: −.87 .84 −.82 .64 .70
P: <.001 <.001 <.001 .02 .01
D- dimer r: .61 −.56 .55 −.72 .70
P: .02 .03 .04 <.01 .01
α2- antiplasmin r: −.69 .62 .63 .75 .73
P: <.01 .04 .04 <.01 <.01
ODmax, maximum optical density, eGFR, estimated glomerular filtration rate; BE, base excess.
TABLE  5 Renal impairment was 
associated with coagulation and 
fibrinolysis activities when calculated with 
Spearman’s correlation
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In addition to routine perioperative coagulation screening, plate-
let counts and function, fibrinogen, FXIII and D- dimer should be 
measured in LPI patients, as inadequate activities can be supported 
with blood products and concentrates. ROTEM was able to identify 
the patients with the most severe coagulation defect and may, par-
ticularly in emergency situations, guide transfusion therapy in LPI 
patients. The role of tranexamic acid in managing hyperfibrinolysis 
associated with lysine deficiency is worth studying.
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